Inamrinone lactate

• CAT Number: I029295
• CAS Number: 75898-90-7
• Molecular Formula: C13H15N3O4
• Molecular Weight: 277.28
• Purity: 98%
• Synonyms: Amrinone lactate, Inamrinone lactate, Inocor
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 3-amino-5-pyridin-4-yl-1H-pyridin-2-one;2-hydroxypropanoic acid
• InChI: InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)
• InChIKey: DOSIONJFGDSKCQ-UHFFFAOYSA-N
• SMILES: CC(C(=O)O)O.C1=CN=CC=C1C2=CNC(=O)C(=C2)N

Inamrinone lactate（Cat No.:I029295）is a phosphodiesterase III inhibitor used to treat heart failure, particularly in acute or severe cases. By inhibiting phosphodiesterase III, it increases cyclic AMP (cAMP) levels within cardiac cells, leading to enhanced contractility (positive inotropy) and improved blood flow. This results in a reduction in symptoms such as shortness of breath and fatigue in patients with heart failure. Inamrinone lactate also causes vasodilation, further aiding in improving cardiac output. It is administered intravenously and is typically used in hospital settings under careful monitoring due to potential side effects like arrhythmias and hypotension.

Reference

1: Endoh M. Amrinone, forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy. Circ Res. 2013 Aug 2;113(4):358-61. doi: 10.1161/CIRCRESAHA.113.301689. PubMed PMID: 23908328.
2: Miller DR. Retraction note to: Amrinone improves contractility of fatigued diaphragm in dogs. Can J Anaesth 1995; 42: 80-6,DOI 10.1007/BF03010577. Can J Anaesth. 2012 Dec;59(12):1176. doi: 10.1007/s12630-012-9838-x. English, French. PubMed PMID: 23184630.
3: Asif M. Phosphodiesterase-III Inhibitors Amrinone and Milrinone on Epilepsy and Cardiovascular Activities. N Am J Med Sci. 2012 Oct;4(10):499-502. doi: 10.4103/1947-2714.102001. PubMed PMID: 23112975; PubMed Central PMCID: PMC3482785.
4: Kucuk C, Akcan A, Akyýldýz H, Akgun H, Muhtaroglu S, Sozuer E. Effects of amrinone in an experimental model of hepatic ischemia-reperfusion injury. J Surg Res. 2009 Jan;151(1):74-9. doi: 10.1016/j.jss.2008.02.008. Epub 2008 Mar 13. PubMed PMID: 18468627.
5: Komamura K, Matsuo H, Sasaki T. Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute. Value Health. 2008 Mar;11 Suppl 1:S39-42. doi: 10.1111/j.1524-4733.2008.00365.x. PubMed PMID: 18387066.
6: Gong SG, Liu JM. [Protection of amrinone against lung injury induced by ischemia/reperfusion in rats]. Zhongguo Dang Dai Er Ke Za Zhi. 2007 Jun;9(3):233-6. Chinese. PubMed PMID: 17582263.
7: Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol. 2005 Nov;97(5):325-32. PubMed PMID: 16236146.
8: Yoo KY, Kim H, Jeong CW, Park HC, Bae HB, Lee J. Effects of inotropic drugs on mechanical function and oxygen balance in postischemic canine myocardium: comparison of dobutamine, epinephrine, amrinone, and calcium chloride. J Korean Med Sci. 2005 Oct;20(5):732-9. PubMed PMID: 16224144; PubMed Central PMCID: PMC2779267.
9: Akcan A, Kucuk C, Ok E, Canoz O, Muhtaroglu S, Yilmaz N, Yilmaz Z. The effect of amrinone on liver regeneration in experimental hepatic resection model. J Surg Res. 2006 Jan;130(1):66-72. Epub 2005 Sep 8. PubMed PMID: 16154150.
10: Ekingen G, Sönmez K, Ozen O, Demirogullari B, Karabulut R, Türkyilmaz Z, Yenidünya S, Ayayvaci S, Basaklar AC, Kale N. Effect of amrinone on mucosal permeability in experimental intestinal ischaemia/reperfusion injury. ANZ J Surg. 2005 Jul;75(7):608-13. PubMed PMID: 15972057.